Answers are grounded in this paper and cite their sources.
Treatment beyond progression with ICIs in patients with HCC is safe and may benefit a subset of patients due to later-onset tumor responses or disease stability. These findings may guide the design of trials testing ICIs in HCC and the use of treatment beyond progression in routine practice.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: